Adjuvant Everolimus Fails to Stop Recurrence in Early High-Risk Breast Cancer
(MedPage Today) -- Adding mTOR inhibitor everolimus (Afinitor) to adjuvant endocrine therapy failed to improve disease-free survival (DFS) in high-risk hormone receptor-positive/HER2-negative (HR+/HER2-), a large randomized trial showed.
Three...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Hematology | HER2 | Hormones